Sökning: WFRF:(Holmstrom Margareta)
> (2017) >
Management of rivar...
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates : a cohort study
-
Majeed, Ammar (författare)
-
- Agren, Anna (författare)
- Karolinska Institutet
-
- Holmstrom, Margareta (författare)
- Karolinska Institutet
-
visa fler...
-
- Bruzelius, Maria (författare)
- Karolinska Institutet
-
- Chaireti, Roza (författare)
- Karolinska Institutet
-
- Odeberg, Jacob, Professor, 1963- (författare)
- Karolinska Institutet,KTH,Science for Life Laboratory, SciLifeLab
-
Hempel, Eva-Lotta (författare)
-
- Magnusson, Maria (författare)
- Karolinska Institutet
-
- Frisk, Tony (författare)
- Karolinska Institutet
-
Schulman, Sam (författare)
-
visa färre...
-
(creator_code:org_t)
- AMER SOC HEMATOLOGY, 2017
- 2017
- Engelska.
-
Ingår i: Blood. - : AMER SOC HEMATOLOGY. - 0006-4971 .- 1528-0020. ; 130:15, s. 1706-1712
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://ashpublicati...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- There is uncertainty regarding the effectiveness and occurrence of thromboembolic events in patients treated with prothrombin complex concentrates (PCCs) for the management of major bleeding events (MBEs) onrivaroxabanor apixaban. We investigated the effectiveness of PCCs given for the management of MBEs in patients on rivaroxaban or apixaban. Between 1 January 2014 and 1 October 2016, we prospectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs. The effectiveness of PCCs was assessed by using the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee criteria for the assessment of the effectiveness of major bleeding management. The safety outcomes were thromboembolic events and all-cause mortality with in 30 days after treatmentwith PCCs. Atotal of 84 patients received PCCs for the reversal of rivaroxaban or apixaban due to a MBE. PCCs were given at amedian (interquartile range) dose of 2000 IU (1500-2000 IU). Intracranial hemorrhage (ICH) was themost common site of bleeding requiring reversal (n = 5 59; 70.2%), followed by gastrointestinal bleeding in 13 (15.5%) patients. Management with PCCs was assessed as effective in 58 (69.1%) patients and ineffective in 26 (30.9%) patients. Most patients with ineffective hemostasis with PCCs had ICH (n 5 16; 61.5%). Two patients developed an ischemic stroke, occurring 5 and 10 days after treatment with PCC. Twenty seven (32%) patients died within 30 days after a MBE. The administration of PCCs for the management of MBEs associated with rivaroxaban or apixaban is effective inmost cases and is associated with a low risk of thromboembolism. Our findings are limited by the absence of a control group in the study.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Majeed, Ammar
-
Agren, Anna
-
Holmstrom, Marga ...
-
Bruzelius, Maria
-
Chaireti, Roza
-
Odeberg, Jacob, ...
-
visa fler...
-
Hempel, Eva-Lott ...
-
Magnusson, Maria
-
Frisk, Tony
-
Schulman, Sam
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet